Research · 2024 to 2025

A 3D nodule pipeline for EGFR/KRAS biomarker prediction

Combined NVIDIA VISTA-3D segmentation with a custom ResNet-18 classifier on LIDC-IDRI to predict EGFR/KRAS biomarkers from lung CT.

Medical imaging3D segmentationResearchEvaluation
92% recall
80% fewer false positives
0.87 AUC

The short answer

In a collaboration between Babeș-Bolyai University and UMF Iuliu Hațieganu, I built a 3D nodule detection pipeline for EGFR/KRAS biomarker prediction using the LIDC-IDRI dataset. It combined NVIDIA VISTA-3D for segmentation with a custom ResNet-18 classifier and reached 92% recall, an 80% reduction in false positives and an AUC of 0.87. Clinical validation later confirmed the results.

Context and role

ContextResearch collaboration · Babeș-Bolyai University and UMF Iuliu Hațieganu · 2024 to 2025
RoleBuilt the detection and classification pipeline, working with Prof. Laura Diosan and clinical collaborators.
CategoryResearch

The problem

Biomarker prediction from lung CT is a 3D problem. Nodules are small, irregular and surrounded by anatomy that produces false positives.

EGFR and KRAS mutations matter for treatment decisions, but the signal is spread across imaging features that are hard to hand-engineer.

A pipeline that finds every nodule is not useful if it buries the radiologist in false positives. Precision and recall have to be balanced against clinical workflow.

Approach

  • Used NVIDIA VISTA-3D for 3D segmentation of lung nodules.
  • Built a custom ResNet-18 classifier for the EGFR/KRAS prediction task on the segmented volumes.
  • Worked with the LIDC-IDRI dataset in a cross-institution collaboration with clinicians.
  • Measured recall, false-positive reduction and AUC rather than a single accuracy number.

What I did not claim

The boundary of a project is part of its evidence. These are the claims this work does not support.

  • This is a research collaboration, not a deployed clinical diagnostic product.
  • The pipeline was validated in a research setting and later confirmed through clinical validation; it is not a medical device.
  • The work was collaborative. The clinical and academic partners contributed domain and validation expertise.
  • No claim of use on live patient data in a hospital deployment.

Results

  • 92% recall on the nodule detection task.
  • An 80% reduction in false positives.
  • An AUC of 0.87 for the classification task.
  • Clinical validation later confirmed the results.
  • The project is evidence that rigorous measurement, not just model choice, is what makes a medical AI result defensible.

Stack

  • Python
  • PyTorch
  • NVIDIA VISTA-3D
  • ResNet-18
  • LIDC-IDRI

What this means for you

The useful part of this project is not the artifact. It is the method: define the measurement first, keep the scope honest, and hand over something your team can run. That method is what transfers to a new problem.

If your situation looks similar, the related services below are the place to start. If it does not, send a short description and I will tell you whether I am the right person.

Boundary: Research collaboration. Not a deployed clinical product or medical device. Results were reported in a research context and later confirmed through clinical validation.

Written by

Marius Boroica is an independent AI automation engineer in Cluj-Napoca, Romania. He designs AI workflows, document pipelines and internal assistants, and connects them to the tools a team already uses. NVIDIA Certified Professional: Gen AI LLMs.

Page last updated: October 2026

Next step

Have a problem in the same shape?

A 30-minute call is enough to see whether the method transfers, and which engagement is the smallest useful one.

Prefer email? boroicamarius01@gmail.com